Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 70 publications
Preclinical Activity of the B7-H3-Targeting Antibody-Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 12, 2025
Improved Outcomes for Older Children, Adolescents, and Young Adults With Neuroblastoma in the Post-Immunotherapy Era: An Updated Report From the International Neuroblastoma Risk Group.
Journal: Pediatric blood & cancer
Published: September 23, 2025
The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivity.
Journal: Research square
Published: August 06, 2025
The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity.
Journal: Nature communications
Published: July 06, 2025
Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 23, 2025
Anaplastic Lymphoma Kinase Inhibition Therapy for Hereditary Neuroblastoma.
Journal: JCO precision oncology
Published: April 28, 2025
Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 04, 2025
Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum.
Journal: Pediatric blood & cancer
Published: February 26, 2025
Lineage dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and -independent immunotherapeutic targets.
Journal: Neuro-oncology
Published: January 18, 2025
A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers.
Journal: Nature communications
Published: December 16, 2024
Lessons learned from 20 years of preclinical testing in pediatric cancers.
Journal: Pharmacology & therapeutics
Published: August 31, 2024
Last Updated: 09/26/2026